{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:28:58Z","timestamp":1791332938399,"version":"4.3.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.beha.2014.10.014","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T14:58:26Z","timestamp":1414421906000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Advances in T-cell therapy for ALL"],"prefix":"10.1016","volume":"27","author":[{"given":"Stephan A.","family":"Grupp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.beha.2014.10.014_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002620050415","article-title":"Tumor-specific T-bodies: towards clinical application","volume":"45","author":"Eshhar","year":"1997","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.beha.2014.10.014_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2014.10.014_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.beha.2014.10.014_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"10.1016\/j.beha.2014.10.014_bib5","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.beha.2014.10.014_bib6","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.beha.2014.10.014_bib7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.beha.2014.10.014_bib8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2014.10.014_bib9","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","author":"Lee","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2014.10.014_bib10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.beha.2014.10.014_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"95","key":"10.1016\/j.beha.2014.10.014_bib12","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1016\/j.beha.2014.10.014_bib13","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2014.10.014_bib14","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2014.10.014_bib15","first-page":"689","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J\u00a0Immunother"},{"issue":"4","key":"10.1016\/j.beha.2014.10.014_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1517\/14712598.8.4.475","article-title":"T\u00a0lymphocyte engineering ex\u00a0vivo for cancer and infectious disease","volume":"8","author":"Levine","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.beha.2014.10.014_bib17","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","article-title":"Effects of CD28 costimulation on long term proliferation of CD4+ T cells in the absence of exogenous feeder cells","volume":"159","author":"Levine","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beha.2014.10.014_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.1997.tb01026.x","article-title":"Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging","volume":"160","author":"Weng","year":"1997","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.beha.2014.10.014_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.beha.2014.10.014_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"issue":"5310","key":"10.1016\/j.beha.2014.10.014_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.276.5310.273","article-title":"Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells","volume":"276","author":"Carroll","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.beha.2014.10.014_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pcl.2009.11.002","article-title":"T-cell-based therapies for malignancy and infection in childhood","volume":"57","author":"Ahmed","year":"2010","journal-title":"Pediatr Clin North Am"},{"issue":"25","key":"10.1016\/j.beha.2014.10.014_bib24","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T\u00a0lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.014_bib25","article-title":"TNF receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome (IPS). A joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Children's Oncology Group (COG) study (ASCT0521)","author":"Yanik","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1016\/j.beha.2014.10.014_bib26","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbmt.2014.02.026","volume":"20","author":"Yanik","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2014.10.014_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V122.21.67.67","article-title":"T\u00a0cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in\u00a0vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL","volume":"122","author":"Grupp","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2014.10.014_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"issue":"26","key":"10.1016\/j.beha.2014.10.014_bib29","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2014.10.014_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.beha.2016.07.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000}}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:04:52Z","timestamp":1761498292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692614000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":29,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1521692614000802"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2014.10.014","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in T-cell therapy for ALL","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2014.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}